|1.||Lilja, Hans: 106 articles (10/2015 - 08/2002)|
|2.||Partin, Alan W: 92 articles (02/2016 - 02/2002)|
|3.||Scardino, Peter T: 91 articles (08/2015 - 03/2002)|
|4.||D'Amico, Anthony V: 86 articles (06/2015 - 03/2002)|
|5.||Freedland, Stephen J: 80 articles (12/2015 - 02/2002)|
|6.||Catalona, William J: 78 articles (02/2016 - 06/2002)|
|7.||Thompson, Ian M: 78 articles (12/2015 - 06/2003)|
|8.||Schröder, Fritz H: 76 articles (11/2015 - 01/2002)|
|9.||Moul, Judd W: 74 articles (12/2014 - 03/2002)|
|10.||Epstein, Jonathan I: 69 articles (09/2015 - 03/2002)|
|1.||Prostatic Neoplasms (Prostate Cancer)
05/01/2012 - "The introduction of serum prostate-specific antigen (PSA) in the 1980s has dramatically altered and benefited the initial diagnosis of prostate cancer. "
02/01/2009 - "Although prostate-specific antigen (PSA) is the best biomarker for predicting prostate cancer, its predictive performance needs to be improved. "
02/01/2008 - "The prostate-specific antigen value and the percent positive biopsy cores can be helpful in identifying men with high-grade prostate cancer most likely to benefit from RP. "
01/01/2004 - "The use of total prostate-specific antigen (tPSA) measurement has dramatically improved the ability to detect prostate cancer at earlier stages. "
01/01/2001 - "Prostate-specific antigen (PSA) has been extremely helpful in the detection of new or recurrent prostate cancer. "
02/01/2014 - "Furthermore, when compared with Duopafei®, the DTX-PMs dramatically reduced the prostate specific antigen (PSA) level and tumor growth of prostate tumor-bearing nude mice in vivo. "
06/01/2011 - "Most tumors respond favorably to these treatments, exhibiting regression of the tumor, amelioration of symptoms, and a decrease of prostate-specific antigen in patient sera. "
09/01/1998 - "This method has been shown to increase the cancer detection rate of prostate biopsy by 35% over the standard sextant biopsy method, and it is most effective in patients with prostate specific antigen less than 10. "
11/01/1990 - "Serum prostate specific antigen measurements may be helpful in stage A1 cancer patients with levels of 1 ng./ml. or less, or greater than 10 ng./ml. in choosing the most appropriate therapy."
01/01/2014 - "Results showed a significant reduction in tumor size, as evidenced by magnetic resonance imaging and color Doppler, as well as a an undetectable level of prostate specific antigen during, and immediately following treatment. "
01/01/2008 - "Instead of relying on serum prostate-specific antigen (PSA) to identify patients for prostate biopsy, new laboratory tests are needed that have improved specificity for prostate carcinoma (CaP), allow accurate classification of clinically insignificant CaPs, allow for detection of clinically significant CaP in patients without elevated serum PSA, and allow for identification of aggressive forms of CaP, which may warrant adjunctive or even molecularly targeted therapy in the future. "
12/01/2001 - "The purpose of this study was to evaluate the efficacy of various diagnostic tests including transrectal ultrasound (TRUS), TRUS guided biopsy, digital rectal examination (DRE), prostate specific antigen (PSA), and prostate specific antigen density (PSAD) in detecting prostatic carcinomas. "
05/15/1995 - "This study was undertaken to assess the predictive value of pretreatment prostate-specific antigen (PSA) and the difference between clinical and PSA disease-free status in patients with long-term follow-up after irradiation for prostatic carcinoma. "
12/01/1995 - "The ratio between free and total prostate-specific antigen (PSA) in serum (F/T ratio) was shown to improve the specificity of total serum PSA for the detection of prostate carcinoma in selected populations. "
12/01/1995 - "The ratio between free and total prostate-specific antigen (PSA) in serum (F/T ratio) was shown to improve the differentiation between prostate carcinoma and benign conditions in selected series of patients. "
|4.||Neoplasm Metastasis (Metastasis)
08/01/2006 - "As expected, patients with skeletal metastases had a significantly greater mean serum total prostate-specific antigen level, and a Gleason sum of 8 or 9 was significantly more frequent in the pathologic findings of these subjects. "
02/01/1999 - "The better efficacy of prostate specific antigen for the prediction of bone metastases was obtained with a cutoff value of 50 ng/ml (sensitivity 72%, specificity 86%). "
08/01/1995 - "Long-term followup data will be needed to determine whether there will be a lower incidence of biochemical relapse as determined by prostate specific antigen, local recurrence or metastasis, with an improvement in patient survival."
03/01/1992 - ""Prostate-specific" immunohistochemical techniques and serum prostate-specific antigen levels may be helpful in determining whether a particular metastases is from the prostate. "
08/01/2005 - "In the present study, we evaluated the relationships between prostate-specific antigen (PSA) level and bone metastasis, between Gleason sum and bone metastasis, and between clinical T stage and bone metastasis in Japanese patients. "
|5.||Prostatic Hyperplasia (Benign Prostatic Hyperplasia)
06/01/2013 - "To investigate the efficacy of total prostate-specific antigen (tPSA) and free prostate-specific antigen (fPSA) for the estimation of prostate volume (PV) in pathologically-proven benign prostatic hyperplasia (BPH) patients. "
08/01/2001 - "From these results, it is evident that Prostane was effective in alleviating symptoms, reducing prostate specific antigen values and normalizing uroflow dynamics in patients with benign prostatic hypertrophy."
12/01/2008 - "It improved patient prostate specific antigen, American Urological Association symptom score and maximum urinary flow rate independent of the amount of benign prostatic hyperplasia present. "
12/01/1995 - "The AUA symptom scores improved on average by 6.3 points; prostatic adenoma volume reduced from baseline by 17%, and the serum prostate specific antigen (PSA) level decreased by 35%. "
12/01/2009 - "This study investigated relationships between total prostate-specific antigen (tPSA), free prostate-specific antigen (fPSA), and prostate volume (PV) in Chinese men with biopsy-proven BPH, and analyzed whether fPSA performed better than tPSA at estimating thresholds of PV. From 2003 to 2008, a total of 286 patients with a PSA less than 10 ng/ml and biopsy proven benign prostatic hyperplasia were included in this study. "
|2.||Biological Markers (Surrogate Marker)
|8.||prostatic acid phosphatase
|1.||Prostatectomy (Retropubic Prostatectomy)
|3.||Drug Therapy (Chemotherapy)